Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on... see more

CSE:QNTM - Post Discussion

Quantum BioPharma Ltd > fsd pharma is legit! Go check them out
View:
Post by dayanpantig on Dec 15, 2020 11:09pm

fsd pharma is legit! Go check them out

 fsd pharma is legit! Go check them out

 
Comment by wendhie05 on Dec 16, 2020 8:55am
This is how FSD Pharma doing it. The US Food and Drug Administration (FDA) has authorized the initiation of a Phase 2 study of FSD-201 on COVID-19 patients. The company plans to start oral dosing (tablets) more than 300 patients in October this year. The company completed a Phase 1 first-in-human safety and tolerability study for FSD201 in Australia. 
Comment by Mil_Man54 on Dec 16, 2020 9:01am
Comment by wendhie05 on Dec 16, 2020 9:01am
Through the acquisition of Prismic Pharmaceuticals in June 2019, FSD Pharma attained the worldwide rights (except for Italy and Spain) of the micronized and ultra-micronized formulations of palmitoylethanolamide (micro-PEA and ultra-micronized-PEA). Prismic had previously acquired the license to conduct R&D and commercialize micronized-PEA and ultra-micronized-PEA as a prescription medication ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities